TitleCT引导125I粒子植入治疗涎腺癌肺转移疗效分析
Other TitlesCT guided 125I implantation in treatment of salivary gland carcinoma with lung metastasis
Authors阎卫亮
霍小东
霍彬
王海涛
郑广钧
柴树德
王俊杰
Affiliation300211,天津医科大学第二医院胸外科
300211,天津医科大学第二医院肿瘤科
100191,北京大学第三医院放疗科
Keywords涎腺癌
肺转移癌
放射性碘-125粒子
CT
Adenocarcinoma of salivary gland
Pulmonary metastasis
125I
CT
Issue Date2017
Publisher中华内分泌外科杂志
Citation中华内分泌外科杂志. 2017, 11(5), 414-416,420.
Abstract目的 探讨CT引导下经皮穿刺放射性125I粒子种植治疗涎腺癌肺转移的疗效.方法 2010年6月至2015年6月间天津医科大学第二医院患者18例,涎腺癌肺转移灶42个,在CT引导下经皮穿刺行125I放射性粒子植入,未给予其他治疗.处方剂量80 Gy,植入后1、2、4及6个月复查CT观察肿瘤体积变化.D90:83 GY,V90:92%.靶区瘤体接受的平均照射剂量为(159.7±35.3)Gy,中位剂量(117.6±26.2)Gy.结果 6个月复查CT显示肿瘤完全缓解(complete response,CR)28.6% (12/42),部分缓解(partial response,PR)57.1%(24/42),稳定(stable disease,SD)9.5%(4/42),进展(progressive disease,PD)4.8%(2/42),总有效率85.7%(36/42).随访1年存活16例(88.9%),2年存活12例(66.7%),3年存活9例(50%).结论 CT引导下经皮穿刺放射性125I粒子种植对涎腺癌肺转移近期疗效肯定.
Objective To evaluate the curative effect of CT guided percutaneous puncture of radioactive 125I seeds in treatment of salivary gland carcinoma with lung metastasis.Methods 18 patients with 42 salivary gland carcinoma of the lung metastases,received CT-guided percutaneous puncture of 125I radioactive particles.No other treatment was given.The prescription dose was 80 Gy.Results After six months,CT showed that the tumor complete remission (CR) rate was 28.6%,(12/42),partial response (PR) 57.1% (24/42),stable disease (SD)9.5% (4/42),progressive disease(PD)4.8% (2/42),and the total effective rate 85.7% (36/42).16 cases survived within 1 year (88.9%),12 cases in 2 years (66.7%),and 9 cases in 3 years (50%).Conclusion CT guided percutaneous puncture of radioactive 125I particles has recent efficacy in treatment of salivary gland carcinoma with lung metastasis in the future.
URIhttp://hdl.handle.net/20.500.11897/511542
ISSN1674-6090
DOI10.3760/cma.j.issn.1674-6090.2017.05.016
Appears in Collections:第三医院

Files in This Work
There are no files associated with this item.

Web of Science®



Checked on Last Week

Scopus®



Checked on Current Time

百度学术™



Checked on Current Time

Google Scholar™





License: See PKU IR operational policies.